insights_auto
Outlook: 18.9% bullish·29.7% bearish
Go to analysischevron_right
MRNA:NASDAQ
Moderna Inc
$198.85
arrow_downward
-0.62%(-1.25) 1D
$195.99
arrow_downward
-1.44% (-2.86)bedtimeAfter hours
Closed: Oct 26, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MRNA...
Open
$186.90
High
$203.82
Low
$181.65
Mkt. cap
79.39B
Avg. vol.
18.59M
Volume
0.00
52-wk high
$254.48
52-wk low
$22.28
EPS
-$7.98
Beta
1.09
Shares outstanding
399.24M
No. of employees
5K
Open
$186.90
High
$203.82
Low
$181.65
Mkt. cap
79.39B
Avg. vol.
18.59M
Volume
0.00
52-wk high
$254.48
52-wk low
$22.28
EPS
-$7.98
Beta
1.09
Shares outstanding
399.24M
No. of employees
5K
News stories
From web sources and news partners
News Corp
·
8 hours ago
Moderna CEO Says Its Cancer Vaccine Isn’t a Disappointment, It’s a Blockbuster
Investor's Business Daily
·
10 hours ago
Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine
News Corp
·
11 hours ago
Moderna’s Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.
The Cryptonomist
·
15 hours ago
Moderna stock trades at $196.9, down 1.6%, with hourly signals bearish
Profile
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In May 2026, Time ranked Moderna first in their list of the World's Most Impactful Companies. Wikipedia
About Moderna Inc